货号:A853008
同义名:
Ly2606368; ACR 368
Prexasertib是一种选择性ATP竞争性CHK1 (Ki 为 0.9 nM,IC50 为 <1 nM) 和CHK2 (IC50=8 nM) 的小分子抑制剂,它阻断CHK蛋白的自磷酸化和随后的激活,从而调节CDC25磷酸酶和周期蛋白依赖性激酶的活性。Prexasertib 引起双链 DNA 断裂和复制突变,导致细胞凋亡。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | Chk1 ↓ ↑ | Chk2 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rabusertib |
++
Chk1, IC50: 7 nM |
99%+ | |||||||||||||||||
PF-477736 |
++++
Chk1, Ki: 0.49 nM |
98%+ | |||||||||||||||||
Prexasertib 2HCl |
++++
Chk1, Ki: 0.9 nM |
++
Chk2, IC50: 8 nM |
RSK | 98% | |||||||||||||||
AZD-7762 |
+++
Chk1, IC50: 5 nM |
++
Chk2, IC50: <10 nM |
99%+ | ||||||||||||||||
CHIR-124 |
++++
Chk1, IC50: 0.3 nM |
PDGFR,FLT3,GSK-3 | 98% | ||||||||||||||||
SCH900776 |
+++
Chk1, IC50: 3 nM |
99%+ | |||||||||||||||||
SAR-020106 |
+
Chk1, IC50: 13.3 nM |
98% | |||||||||||||||||
CCT245737 |
+++
Chk1, IC50: 1.4 nM |
97+% | |||||||||||||||||
BML-277 |
+
Chk2, IC50: 15 nM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
描述 | Prexasertib (LY2606368) is distinguished as a highly selective and ATP-competitive second-generation inhibitor of checkpoint kinase 1 (CHK1), possessing a Ki value of 0.9 nM and an IC50 of less than 1 nM. Its ability to inhibit CHK1 with such potency underlines its mechanism of action, which involves causing double-stranded DNA breaks and replication catastrophe, leading to apoptosis. Beyond CHK1, Prexasertib exhibits inhibition against CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM), demonstrating its broad spectrum of action against other kinases involved in cell cycle regulation and tumor growth[1].[2]. |
体内研究 | In vivo, Prexasertib demonstrates significant anti-tumor efficacy in tumor xenograft models, with dosing regimens leading to growth inhibition. Specifically, when administered subcutaneously at doses ranging from 1-10 mg/kg twice daily for three days with rest periods, it effectively inhibits tumor growth. Additionally, a dose of 15 mg/kg results in CHK1 inhibition in the blood and increased phosphorylation of H2AX (S139) and RPA2 (S4/S8), markers associated with DNA damage and stress responses[1]. |
体外研究 | Additionally, Prexasertib shows inhibition against a range of other kinases, including MELK (IC50=38 nM), SIK (IC50=42 nM), BRSK2 (IC50=48 nM), and ARK5 (IC50=64 nM), indicating its multi-targeted approach in cancer therapy. It has been noted that the efficacy of LY2606368 in causing DNA damage is dependent on the presence of CDC25A and CDK2, key regulators of cell cycle progression[1]. In cellular assays, Prexasertib has demonstrated significant impact on DNA integrity and cell cycle dynamics. For instance, treatment with Prexasertib results in DNA damage during the S-phase in HeLa cells and inhibits CHK1 and CHK2 autophosphorylation in HT-29 cells, affecting the cells' ability to respond to DNA damage and replication stress[1]. Furthermore, at a concentration of 4 nM for 24 h, it induces a notable shift in cell-cycle populations from G1 and G2-M to S-phase in U-2 OS cells, coupled with the induction of H2AX phosphorylation, a marker of DNA damage[1]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.74mL 0.55mL 0.27mL |
13.68mL 2.74mL 1.37mL |
27.37mL 5.47mL 2.74mL |
CAS号 | 1234015-52-1 |
分子式 | C18H19N7O2 |
分子量 | 365.39 |
SMILES Code | N#CC1=NC=C(NC2=NNC(C3=C(OC)C=CC=C3OCCCN)=C2)N=C1 |
MDL No. | MFCD25977016 |
别名 | Ly2606368; ACR 368 |
运输 | 蓝冰 |
InChI Key | DOTGPNHGTYJDEP-UHFFFAOYSA-N |
Pubchem ID | 46700756 |
存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
溶解方案 |
DMSO: 16 mg/mL(43.79 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|